Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 2/20 | 0.59 |
| ▸ | FEN1 | P39748 | 2/20 | 0.59 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.59 |
| ▸ | DNASE1 | P24855 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR1F | P30939 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17335950 | 0.99 | ERCC1 (0.58) | ERCC1FEN1ERCC4DNASE1HPGD | |
| SCHEMBL17335954 | 0.94 | ERCC1 (0.55) | ERCC1FEN1ERCC4DNASE1HPGD | |
| SCHEMBL17347878 | 0.89 | ERCC1 (0.59) | ERCC1FEN1ERCC4DNASE1HPGD | |
| SCHEMBL17335963 | 0.89 | HPGD (0.47) | ERCC1FEN1ERCC4DNASE1HPGD | |
| SCHEMBL17335957 | 0.85 | HPGD (0.51) | HPGDALDH1A1KDM4EACHEADRA1B | |
| SCHEMBL10084674 | 0.82 | HPGD (0.53) | HPGDALDH1A1KDM4EACHEKMT2A | |
| SCHEMBL17335952 | 0.81 | ERCC1 (0.62) | ERCC1FEN1ERCC4DNASE1HPGD | |
| SCHEMBL17335955 | 0.81 | ERCC1 (0.62) | ERCC1FEN1ERCC4DNASE1HPGD | |
| SCHEMBL18763298 | 0.81 | CTSS (0.44) | HPGDALDH1A1KDM4EADRA1BKMT2A | |
| SCHEMBL17347738 | 0.80 | ERCC1 (0.61) | ERCC1FEN1ERCC4DNASE1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015189595-A1 | TREATMENT OF CHAGAS DISEASE | UNIVERSITY OF DUNDEE (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | ERCC1 2255/4885FEN1 4772/4885ERCC4 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.